Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot.
Vericiguat, a novel soluble guanylate cyclase stimulator, reduced the incidence of cardiovascular death or hospitalization for HF in a population of high-risk patients with heart failure with reduced ejection fraction （HFrEF ）who had recently been hospitalized or received intravenous diuretic therapy.Given the increasing incidence of patients with ACS and its challenges posing to life，investigators intend to conduct a prospective observational study. Investigators choose several meaningful endpoints including the time of cardiovascular death or heart failure（HF) hospitalization、inflammatory markers、the value of N-terminal pro-B-type natriuretic peptide(NT-proBNP)、results of echocardiogram and life quality score.By collecting these datas and work on a group of analysis ，investigators evaluate whether differences exsit in ACS patients with ejection \<45% between participants who take vericiguat regularly and those who donot.
Study Type
OBSERVATIONAL
Enrollment
149
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
a composite of death from cardiovascular causes or first hospitalization for heart failure
Time frame: from baseline to one year
results of echocardiogram
changes in left ventricular ejection fraction during the follow-up
Time frame: from baseline to one year
the numerical value of NT-proBNP
an important biomarker of heart failure
Time frame: from baseline to one year
life quality score
Investigators choose Kansas City Cardiomyopathy Questionnaire(KCCQ) to evaluate life quality of participants.
Time frame: from baseline to one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.